Vallisitaram Kodali, MD
Gastroenterology · New Orleans, LANPI 1609809920
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $708 and has fallen 90.4% since, to $68 in 2024. That places this record below the midpoint for gastroenterology clinicians in LA, where the typical reported total is $3,631.
Across 76 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$302
- Takeda Pharmaceuticals U.S.A., Inc.$183
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$126
- QOL Medical, LLC$112
- Lucid Diagnostics Inc.$108
- Redhill Biopharma Inc.$104
- plus $479 from 14 others
Across 6 payments — averaging $4597.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$28K
What the payments were for
- Food & beverage$1,40099%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $302 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $183 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $126 |
| QOL Medical, LLC | 8 | $112 |
| Lucid Diagnostics Inc. | 1 | $108 |
| Redhill Biopharma Inc. | 6 | $104 |
| Abbott | 1 | $92 |
| Johnson & Johnson(2 entities) | 3 | $54 |
| Braintree Laboratories, Inc. | 4 | $49 |
| Pfizer | 2 | $49 |
| Ferring Pharmaceuticals Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Organon | 1 | $29 |
| Amgen | 1 | $24 |
| Bristol Myers Squibb | 1 | $23 |
| Lilly USA, LLC | 1 | $18 |
| Merck | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $16 |
| Celltrion USA Inc. | 1 | $15 |
How this compares
$1,415 in reported general payments places this provider in the 25th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 33 | $272 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in New Orleans
- Sarah GloverNew Orleans$274K
- Nisha LoganantharajNew Orleans$173K
- Shamita ShahNew Orleans$114K
- Vivek HuilgolNew Orleans$37K
- Arnab RayNew Orleans$26K
- Janak ShahNew Orleans$18K
- Stephen LandreneauNew Orleans$17K
- Virendra JoshiNew Orleans$16K
- Parth ParekhNew Orleans$10K
- Jonathon ChapmanBaton Rouge$998K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.